ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine

Nyheter ExpreS2ion Biotech Nyheter alla bolag

Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine

REG

CEO Bent Frandsen comments:

"We are pleased to announce that the completion of Bavarian Nordic's clinical Phase III study for the COVID-19 vaccine ABNCoV2 has triggered a milestone payment to AdaptVac, in which ExpreS2ion holds a 34% ownership. The Phase III study served to validate our ExpreS2 technology platform, forming the basis for our ongoing therapeutic HER2+ breast cancer vaccine candidate, ES2B-C001, and future initiatives."

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

Datum	2024-02-21, kl 09:00
Källa	Cision

Bifogade filer

240221 EXPRS2 PR AV Ph3 milestone payment

LOGGA IN

ExpreS2ion Biotech

ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine